Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms

被引:114
作者
Chen, Suet Ching [1 ,2 ]
Brooks, Rebecca [1 ]
Houskeeper, Jessica [2 ]
Bremner, Shaun K. [2 ]
Dunlop, Julia [2 ]
Viollet, Benoit [4 ,5 ,6 ]
Logan, Pamela J. [3 ]
Salt, Ian P. [3 ]
Ahmed, S. Faisal [1 ]
Yarwood, Stephen J. [7 ]
机构
[1] Univ Glasgow, Sch Med, Dev Endocrinol Res Grp, Glasgow G51 4TF, Lanark, Scotland
[2] Univ Glasgow, Inst Mol Cell & Syst Biol, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland
[3] Univ Glasgow, Inst Cardiovasc & Med Sci, Univ Ave, Glasgow G12 8QQ, Lanark, Scotland
[4] Inst Cochin, U1016, INSERM, Paris, France
[5] CNRS, UMR8104, Paris, France
[6] Univ Paris 05, Sorbonne Paris Cite, Paris, France
[7] Heriot Watt Univ, Inst Biol Chem Biophys & Bioengn, Edinburgh Campus, Edinburgh EH14 4AS, Midlothian, Scotland
基金
英国生物技术与生命科学研究理事会;
关键词
Adipogenesis; Osteogenesis; Metformin; Diabetes; AMPK; Mesenchymal stem cells; MESENCHYMAL STEM-CELLS; ANTIDIABETIC DRUG METFORMIN; ADIPOCYTE DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; DIABETES-MELLITUS; MAMMALIAN TARGET; UPSTREAM KINASE; 3T3-L1; CELLS; PPAR-GAMMA; CROSS-TALK;
D O I
10.1016/j.mce.2016.11.011
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
People with Type 2 diabetes mellitus (T2DM) have reduced bone mineral density and an increased risk of fractures due to altered mesenchymal stem cell (MSC) differentiation in the bone marrow. This leads to a shift in the balance of differentiation away from bone formation (osteogenesis) in favour of fat cell development (adipogenesis). The commonly used anti-diabetic drug, metformin, activates the osteogenic transcription factor Runt-related transcription factor 2 (Runx2), which may suppress adipogenesis, leading to improved bone health. Here we investigate the involvement of the metabolic enzyme, AMP-activated protein kinase (AMPK), in these protective actions of metformin. The anti-adipogenic actions of metformin were observed in multipotent C3H10T1/2 MSCs, in which metformin exerted reciprocal control over the activities of Runx2 and the adipogenic transcription factor, PPAR gamma, leading to suppression of adipogenesis. These effects appeared to be independent of AMPK activation but rather through the suppression of the mTOR/p70(S6K) signalling pathway. Basal AMPK and mTOR/p70(S6K) activity did appear to be required for adipogenesis, as demonstrated by the use of the AMPK inhibitor, compound C. This observation was further supported by using AMPK knockout mouse embryo fibroblasts (MEFs) where adipogenesis, as assessed by reduced lipid accumulation and expression of the adipogeneic transcription factor, C/EBP beta, was found to display an absolute requirement for AMPK. Further activation of AMPK in wild type MEFS, with either metformin or the AMPK-specific activator, A769662, was also associated with suppression of adipogenesis. It appears, therefore, that basal AMPK activity is required for adipogenesis and that metformin can inhibit adipogenesis through AMPK-dependent or-independent mechanisms, depending on the cellular context. (C) 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license.
引用
收藏
页码:57 / 68
页数:12
相关论文
共 57 条
[1]
Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO
[2]
2-V
[3]
Convergence of IPMK and LKB1-AMPK Signaling Pathways on Metformin Action [J].
Bang, Sookhee ;
Chen, Yong ;
Ahima, Rexford S. ;
Kim, Sangwon F. .
MOLECULAR ENDOCRINOLOGY, 2014, 28 (07) :1186-1193
[4]
Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis [J].
Bergeron, R ;
Ren, JM ;
Cadman, KS ;
Moore, IK ;
Perret, P ;
Pypaert, M ;
Young, LH ;
Semenkovich, CF ;
Shulman, GI .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (06) :E1340-E1346
[5]
REGULATED EXPRESSION OF 3 C/EBP ISOFORMS DURING ADIPOSE CONVERSION OF 3T3-L1 CELLS [J].
CAO, ZD ;
UMEK, RM ;
MCKNIGHT, SL .
GENES & DEVELOPMENT, 1991, 5 (09) :1538-1552
[6]
Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? [J].
Chen, Q. ;
Shou, P. ;
Zheng, C. ;
Jiang, M. ;
Cao, G. ;
Yang, Q. ;
Cao, J. ;
Xie, N. ;
Velletri, T. ;
Zhang, X. ;
Xu, C. ;
Zhang, L. ;
Yang, H. ;
Hou, J. ;
Wang, Y. ;
Shi, Y. .
CELL DEATH AND DIFFERENTIATION, 2016, 23 (07) :1128-1139
[7]
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome [J].
Cool, Barbara ;
Zinker, Bradley ;
Chiou, William ;
Kifle, Lemma ;
Cao, Ning ;
Perham, Matthew ;
Dickinson, Robert ;
Adler, Andrew ;
Gagne, Gerard ;
Iyengar, Rajesh ;
Zhao, Gang ;
Marsh, Kennan ;
Kym, Philip ;
Jung, Paul ;
Camp, Heidi S. ;
Frevert, Ernst .
CELL METABOLISM, 2006, 3 (06) :403-416
[8]
Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture [J].
Cortizo, AM ;
Sedlinsky, C ;
McCarthy, AD ;
Blanco, A ;
Schurman, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 536 (1-2) :38-46
[9]
Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus [J].
Cusi, K ;
Consoli, A ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (11) :4059-4067
[10]
Day C., 2007, COMPREHENSIVE PHARM, P1